Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer

Daraxonrasib, an oral RAS inhibitor therapy, demonstrated promising results in a phase 1/2 trial involving pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC), reported in the New England Journal of Medicine. Led by The University of Texas MD Anderson Cancer Center, the study highlighted the potential of daraxonrasib as a new treatment option for patients who have progressed after platinum-based chemotherapy and immunotherapy.

The dose range of 160–220 mg yielded a 42% objective response rate, with a median response duration of 11.5 months, median progression-free survival of 8.3 months, and median overall survival of 16 months. While the therapy came with notable toxicities, they were largely manageable in comparison to the alternatives available.